Clinical Study of Irinotecan Liposome Combination Therapy for Advanced Gastric Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2027-10-15
Target enrollment:
Participant gender:
Summary
This study is a single-arm, single-center, exploratory clinical study. It is expected that 44 patients with advanced gastric and gastroesophageal junction adenocarcinoma with first-line treatment failure will be included to receive irinotecan liposomes combined with cindilizumab and renvalatinib. The study unit is the First Affiliated Hospital of Xi'an Jiaotong University. The study included screening period (28 days), treatment period (6 cycles), and follow-up period. Subjects signed the informed consent and underwent baseline examination during the screening period, patients meeting the exclusion criteria entered the treatment period, and all subjects completed the protocol to observe safety, tolerability and efficacy. The same subject received only one dosing schedule during the study period. The follow-up period begins after the end of the treatment period.
Phase:
PHASE4
Details
Lead Sponsor:
First Affiliated Hospital Xi'an Jiaotong University